These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11709200)

  • 1. Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation.
    Rozalski M; Boncler M; Golanski J; Watala C
    Biochem Pharmacol; 2001 Nov; 62(10):1399-408. PubMed ID: 11709200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100?
    Watala C; Golanski J; Rozalski M; Boncler MA; Luzak B; Baraniak J; Korczynski D; Drygas W
    Thromb Res; 2003 Mar; 109(5-6):299-306. PubMed ID: 12818254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a new platelet glycoprotein IIb/IIIa antagonist, SR121566, on platelet activation, platelet-leukocyte interaction and thrombin generation.
    Li N; Wallén NH; Savi P; Hérault JP; Herbert JM
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):507-15. PubMed ID: 9819001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
    Graff J; Klinkhardt U; Harder S
    Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K; Cissé-Thiam M; Drouet L
    Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa.
    Frojmovic MM; Kasirer-Friede A; Goldsmith HL; Brown EA
    Thromb Haemost; 1997 Mar; 77(3):568-76. PubMed ID: 9066012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery.
    Matsuno H; Kozawa O; Niwa M; Tanabe K; Ichimaru K; Takiguchi Y; Yokota M; Hayashi H; Uematsu T
    Thromb Haemost; 1998 Apr; 79(4):865-71. PubMed ID: 9569206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of platelet GPIIB-IIIA (Integrin alphaII(b)beta(3)) in flowing human blood leads to passivation of prothrombotic surfaces.
    Riederer MA; Ginsberg MH; Steiner B
    Thromb Haemost; 2002 Nov; 88(5):858-64. PubMed ID: 12428106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
    Cook NS; Zerwes HG; Tapparelli C; Powling M; Singh J; Metternich R; Hagenbach A
    Thromb Haemost; 1993 Sep; 70(3):531-9. PubMed ID: 8259560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity.
    Hu H; Zhang W; Li N
    J Thromb Haemost; 2003 Aug; 1(8):1805-12. PubMed ID: 12911597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation.
    Boncler MA; Golanski J; Paczuski R; Watala C
    J Mol Med (Berl); 2002 Dec; 80(12):796-801. PubMed ID: 12483465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the binding of 3H-SR121566, an inhibitor of Gp IIb-IIIa activation.
    Savi P; Zamboni G; Rescanières O; Herbert JM
    Thromb Haemost; 2001 Apr; 85(4):702-9. PubMed ID: 11341508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.
    Jeske WP; Walenga JM; Szatkowski E; Ero M; Herbert JM; Haas S; Bakhos M
    Thromb Res; 1997 Nov; 88(3):271-81. PubMed ID: 9526947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.